Ki67 immunostaining in primary breast cancer: pathological and clinical associations.
about
PCNA and Ki67 expression in breast carcinoma: correlations with clinical and biological variablesThe cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteinsThe prognostic relevance of estimates of proliferative activity in early breast cancer.Proliferation markers in tumours: interpretation and clinical value.The proliferation-associated Ki-67 protein: definition in molecular terms.Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer.Counting of apoptotic cells: a methodological study in invasive breast cancerOestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer.Postmastectomy radiotherapy for locally advanced breast cancer receiving neoadjuvant chemotherapy.Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance.Ki67 protein: the immaculate deception?Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodiesMeasuring proliferation in breast cancer: practicalities and applications.Diet and body constitution in relation to subgroups of breast cancer defined by tumour grade, proliferation and key cell cycle regulators.Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value.Inhibition of growth of normal and human papillomavirus-transformed keratinocytes in monolayer and organotypic cultures by interferon-gamma and tumor necrosis factor-alphaHER-2/neu oncogene expression and proliferation in breast cancers.Prognostic significance of a formalin-resistant nuclear proliferation antigen in mammary carcinomas as determined by the monoclonal antibody Ki-S1Proliferative activity is a significant prognostic factor in male breast carcinomaEffect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status.Cell kinetics: an independent prognostic variable in stage II melanoma of the skinAn immunohistochemical assessment of cellular proliferation markers in head and neck squamous cell cancersInfluence of the antioestrogen tamoxifen on normal breast tissueAssessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival.The prognostic significance of DNA flow cytometry in breast cancer: results from 881 patients treated in a single centre.Tumour angiogenesis and tumour cell proliferation as prognostic indicators in gastric carcinoma.Overexpression of the stathmin gene in a subset of human breast cancer.MIB-1 labelling index is an independent prognostic marker in primary breast cancer.The prognostic significance of tumour cell proliferation in squamous cell carcinomas of the oesophagus.The cell cycle regulator ecdysoneless cooperates with H-Ras to promote oncogenic transformation of human mammary epithelial cells.Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients.Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancerMagnetic resonance imaging of breast lesions--a pathologic correlation.Histamine, mast cells and tumour cell proliferation in breast cancer: does preoperative cimetidine administration have an effect?CognitionMaster: an object-based image analysis frameworkHigh-throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association ConsortiumPrognostic value of proliferating cell nuclear antigen in gastric carcinoma.Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil– epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neSecurin promotes the identification of favourable outcome in invasive breast cancer.BMVC test, an improved fluorescence assay for detection of malignant pleural effusions
P2860
Q24564546-68D06F24-BF3F-47F6-B65C-50D4B74E6074Q28118875-D6C5BBB9-C158-413E-8186-4FD285035403Q31028293-1D344B2F-7056-43A6-909D-10C35DD2BC69Q33534215-08984D38-7B55-4E76-B237-45139943BDECQ33721488-3A662C69-D995-4703-8FE7-C59AE6160931Q33834430-A41BC4AE-B286-457C-9E3F-1BE8BD514B6EQ33841332-F74B0786-533E-4762-BD1A-13B7A12EE616Q33842800-71C2821D-7FC3-484F-9070-60B7B3B2F95BQ33876719-DD42BBFC-1477-48F2-8021-E83B609179CEQ33903965-2F0AC4C9-8FCC-4DB2-854D-13500EC9C2C4Q34570709-4FE7AAC2-3112-417D-8BDE-4122A144173BQ34775344-F8275DA4-7FEE-4750-A369-1A3C2A4AF92CQ35633693-CFD20BA4-7337-47BD-A375-568D262BADCAQ35749411-B68D0704-7AA7-4512-959F-9B17E34528A3Q35764646-0533F7A4-D057-44A8-8472-EF2B45B339D4Q35794881-A56C5C21-68F0-44FF-BC28-DE227FB42B1FQ35812090-5AC6C493-D0E8-4A85-A6FE-A5C4104A350FQ35832326-4FC1C8A9-5BC2-4A14-BC59-B5CCAFE237F4Q35833969-46259213-D9BC-4058-A7D6-0BAA798FFB62Q35976106-265F9F2B-FF57-4504-85A1-9EBE7A6D18A6Q35982206-71E3A48E-0114-4A48-B3F2-0BEB551E941CQ35982642-38395784-DF8C-45D8-9B2F-21B22786D68FQ35993847-7A30ADFC-9783-4A07-84D6-E40324BC9E27Q36079823-7D6DD380-55A3-475C-8603-5D554D8887F7Q36079907-7244187C-230F-420C-B779-66D1E91840D9Q36081488-4D11DEF1-E086-45FC-A2C3-D14A23313090Q36114982-04FF7E97-EBD5-4685-B24A-3E3D8523C3A0Q36115384-D2E159E3-2DA1-4E3B-A223-6CC6E419622AQ36141048-E602C63E-B233-4DAC-9977-9C7BE4E1D0EEQ36188646-0A12FAC4-D660-4497-AE9A-5ADF85CBEFECQ36609527-E29A3840-158C-453C-833D-4DE11D27FAC9Q36615792-8B5DDCAE-0F5A-419D-B712-C4496366E9F5Q36620537-6F4E98BE-C73E-4516-8F48-9D2917BF036DQ36620807-71E7C10E-7E8E-4EAE-A157-BC03C043353CQ36767563-6FF0AF6D-9862-4B31-B3EA-0BECDB2812E5Q37121271-09F27CF5-CEA9-42ED-9AEB-444A7234B4DAQ37140501-25444E19-44E9-45FA-B5FC-67CB9501A98EQ37302415-DADC80E1-010E-4D4D-9D30-C29F56F07F48Q37345354-9AAE2A19-EC39-4C71-8C24-789C3C9615B0Q37595275-781199C4-4AB4-42BF-A005-18365E58BA48
P2860
Ki67 immunostaining in primary breast cancer: pathological and clinical associations.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
Ki67 immunostaining in primary breast cancer: pathological and clinical associations.
@ast
Ki67 immunostaining in primary breast cancer: pathological and clinical associations.
@en
type
label
Ki67 immunostaining in primary breast cancer: pathological and clinical associations.
@ast
Ki67 immunostaining in primary breast cancer: pathological and clinical associations.
@en
prefLabel
Ki67 immunostaining in primary breast cancer: pathological and clinical associations.
@ast
Ki67 immunostaining in primary breast cancer: pathological and clinical associations.
@en
P2093
P2860
P356
P1476
Ki67 immunostaining in primary breast cancer: pathological and clinical associations.
@en
P2093
Bouzubar N
Griffiths K
Nicholson RI
Robertson JF
P2860
P2888
P304
P356
10.1038/BJC.1989.200
P407
P50
P577
1989-06-01T00:00:00Z